Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FP-018
- Development stage
- Preclinical
- Lead developer
- Foresee Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Subcutaneous, Intramuscular
01
Overview
FP-018 is a long-acting injectable (LAI) formulation of cariprazine, a small molecule atypical antipsychotic. It is being developed by Foresee Pharmaceuticals using their proprietary Stabilized Injectable Formulation (SIF) platform technology. Cariprazine acts as a partial agonist at dopamine D3 and D2 receptors, with a unique preference for the D3 subtype, and at serotonin 5-HT1A receptors. The SIF platform is designed to provide a sustained-release profile, potentially allowing for monthly or less frequent dosing, which aims to improve medication adherence in patients with schizophrenia and bipolar disorder. FP-018 is currently in the preclinical stage of development.
- Other names
- Cariprazine LAICariprazine Long-Acting Injectable
02
Targets
DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on FP-018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FP-018.